Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
In a report released on January 24, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of ...
12d
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
"Weighing benefits and risksThe greatest risk increases were seen for nausea and vomiting, kidney stones, gastroesophageal ...
Medicare covers sleep tests if you experience clinical signs and symptoms of sleep apnea, narcolepsy, or parasomnia. But there are some limitations depending on what condition is being screened for.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback